CEN Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $520,830 last year. Net change in cash is therefore $191,290.
Cash Flow
| 2014 | -3.23M | -8.24M | 11.52M |
|---|---|---|---|
| 2015 | -263.81K | -47.67K | 270.07K |
| 2016 | -682.14K | -425.9K | 1.16M |
| 2017 | -2.17M | -510.72K | 2.71M |
| 2018 | -1.72M | -105.43K | 1.74M |
| 2019 | -869.35K | -190K | 1.05M |
| 2020 | -340.74K | -130.1K | 469K |
| 2021 | -335.50K | 9.93K | 520.83K |
| 2022 | -335.50K | 9.93K | 520.83K |
CENBF Cash Flow Statement (2014 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.90K | 1.90K | 3.75K | 3.19K | 84.97K | 62.38K | 3.01K | 44.43K | -11.47M |
Operating activities | |||||||||
Net income | -1.51M | -18.90M | 14.24M | -5.65M | -7.53M | -14.08M | -7.58M | -2.40M | -3.16M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 489.11K | 461.70K | 435.53K | 443.19K | 439.04K | 1.76K | 45.60K | 0 | 0 |
Stock-based compensation expense | 552.68K | 15.39M | 746.3K | 1.17M | 0 | 9.36M | 10K | 0 | 0 |
| Deferred income tax benefit | 552.68K | 15.39M | 746.3K | 1.17M | 0 | 9.36M | 10K | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 28.74K | 14.17K | 310.11K | -5.20K | 0 | -222.56K | 0 | 0 | 0 |
Inventories | 0 | 529.78K | -310.11K | 5.20K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.85K | 182.76K | 5.84K | -36.00K | 160.92K | -126.15K | 102.97K | 613.24K | 0 |
Cash generated by operating activities | -335.50K | -335.50K | -340.74K | -869.35K | -1.72M | -2.17M | -682.14K | -263.81K | -3.23M |
Investing activities | |||||||||
Purchases Of Investments | 0 | -120K | -131.90K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -129.53K | -129.53K | 0 | 0 | -5.43K | -160.72K | -7.83K | -47.67K | -8.24M |
Acquisitions Net | 259.47K | 259.47K | 1.80K | -190K | -100K | -350K | 0 | 0 | 0 |
Cash generated by investing activities | 9.93K | 9.93K | -130.1K | -190K | -105.43K | -510.72K | -425.9K | -47.67K | -8.24M |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -10 | 0 | 0 | 0 |
Repayments of term debt | 520.83K | -50K | -30K | 1.05M | -423.23K | 2.71M | 0 | 270.07K | 0 |
Cash used in financing activities | 520.83K | 520.83K | 469K | 1.05M | 1.74M | 2.71M | 1.16M | 270.07K | 11.52M |
Net Change In Cash | 191.29K | 191.29K | -1.84K | 564 | -81.78K | 22.59K | 59.36K | -41.41K | 11.52M |
Cash at end of period | 193.19K | 193.19K | 1.90K | 3.75K | 3.19K | 84.97K | 62.38K | 3.01K | 44.43K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |